The University of Kansas Medical Center
Welcome,         Profile    Billing    Logout  
 258 Trials 
717 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Long, Teresa D
Sleep SMART, NCT03812653: Sleep for Stroke Management and Recovery Trial

Recruiting
N/A
3062
US
CPAP
University of Michigan, National Institute of Neurological Disorders and Stroke (NINDS), FusionHealth LLC, Medical University of South Carolina, University of Cincinnati
Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
11/26
11/26
Lynch, Sharon G
REMODEL-2, NCT05156281 / 2020-005929-89: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting
3
800
Europe, Canada, Japan, US, RoW
Remibrutinib, LOU064, Teriflunomide
Novartis Pharmaceuticals, Novartis Pharma AG
Relapsing Multiple Sclerosis
04/26
10/30
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Recruiting
3
2060
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)

Recruiting
2
275
Europe, US, RoW
BIIB091, DRF, Placebo
Biogen
Relapsing Forms of Multiple Sclerosis
07/25
11/26
MoveS-it, NCT04602390: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Completed
1
33
US
ANK-700, Placebo
Anokion SA
Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
04/24
04/24
NCT02740361: Online Program to Reduce Depression in MS

Active, not recruiting
N/A
400
Europe, US
Deprexis, DeprexisPlus
Charite University, Berlin, Germany, National Multiple Sclerosis Society, Universitätsklinikum Hamburg-Eppendorf, Cedars-Sinai Medical Center, University of Missouri, Kansas City, Penn State University, King's College London, University Medical Center Goettingen, NeuroCure Clinical Research Center, Charite, Berlin
Multiple Sclerosis
01/21
12/21
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
Pahwa, Rajesh
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Terminated
2
513
Europe, US, RoW
K0706, placebo
Sun Pharma Advanced Research Company Limited
Early Parkinson Disease
04/24
06/24
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Active, not recruiting
2
160
Europe, US
Neflamapimod, VX-745, Placebo
EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc
Dementia With Lewy Bodies
08/24
03/25
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Active, not recruiting
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
10/24
02/25
LUMA, NCT05348785 / 2021-004849-20: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Recruiting
2
80
US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
APPRISE, NCT03741920: Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status

Active, not recruiting
N/A
231
US
Personal KinetiGraph™ (PKG™)
Global Kinetics Corporation
Parkinson Disease
02/21
12/24
PDGENE, NCT04057794: PDGeneration: Mapping the Future of Parkinson's Disease

Active, not recruiting
N/A
1982
US
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Fulgent Laboratories, Indiana University, The Parkinson Study Group, Navitas Clinical Research, Inc
Parkinson's Disease and Parkinsonism
12/21
04/25
NCT05842434: Pilot Study of the Felix System in Patients With Essential Tremor and Parkinson's Tremor

Completed
N/A
40
US
Felix
Fasikl Inc.
Essential Tremor, Parkinson Disease
11/23
11/23
TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

Active, not recruiting
N/A
126
US, RoW
Felix NeuroAI Wristband, Sham Device
Fasikl Inc.
Essential Tremor
11/24
11/25
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting
N/A
25000
Canada, US, RoW
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group
Parkinson's Disease
12/24
06/25
ADROIT, NCT04071847: Abbott DBS Post-Market Study of Outcomes for Indications Over Time

Recruiting
N/A
1000
Europe, US, RoW
Deep Brain Stimulation (DBS)
Abbott Medical Devices
Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia, Primary Dystonia, Secondary Dystonia
09/29
09/30
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting
N/A
4500
Europe, Canada, US, RoW
Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders
Parkinson Disease
12/33
12/33
Taylor, Ryan
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.
Primary Biliary Cholangitis
11/24
02/25
Holzbeierlein, Jeffrey M
LaserEn, NCT04979156: SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors

Recruiting
N/A
20
US
SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors, TURBT En Bloc
University of Kansas Medical Center
Bladder Cancer, Surgery
12/24
12/24
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Lakkireddy, Dhanunjaya
DASH-AF, NCT04473807: Feasibility and Safety of IV Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy

Recruiting
4
80
US
Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation, Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy
Kansas City Heart Rhythm Research Foundation, Texas Cardiac Arrhythmia Research Foundation, Munson Medical Center
Arrhythmias, Cardiac, Atrial Fibrillation
04/22
06/22
NCT05575999: Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain

Not yet recruiting
1
200
US
Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination
Kansas City Heart Rhythm Research Foundation, Cardiac Arrhythmia Service, Loma Linda University Health, Loma Linda, CA
Pain Management
10/25
12/25
Amulet IDE, NCT02879448: AMPLATZER™ Amulet™ LAA Occluder Trial

Completed
N/A
1878
Europe, Canada, US, RoW
Amulet Left Atrial Appendage Occluder, WATCHMAN Left Atrial Appendage Closure
Abbott Medical Devices
Stroke
12/20
05/24
NCT04499807: Accuracy of Rhythm Detection by a Wearable Smart Watch for Cardiac Arrhythmias (The WATCH-RHYTHM Study)

Terminated
N/A
16
US
AFib detection with wearable smart watch
Kansas City Heart Rhythm Research Foundation
Atrial Fibrillation
03/21
03/21
aMAZE, NCT02513797: Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation

Active, not recruiting
N/A
600
US
LARIAT + PVI, Left Atrial Appendage ligation + Pulmonary Vein Isolation, Pulmonary Vein Isolation
AtriCure, Inc.
Atrial Fibrillation
04/21
03/22
ER2EP, NCT04476524: Clinical and Economic Impact of an Organized Treatment Pathway on AFib Patient Management From the ER

Recruiting
N/A
200
US
Quality improvement, All patients with AF as primary problem treated with study protocol would be compared with historical cohort of AF patients who were treated with routine care in the ER.
Kansas City Heart Rhythm Research Foundation
Cardiac Arrhythmia, Atrial Fibrillation
11/21
12/21
NCT04471584: Comparative Analysis in Detection of Atrial Arrhythmia and ECG Quality in Three Different Insertable Cardiac Monitors

Recruiting
N/A
150
US
Insertion of ILR device
Kansas City Heart Rhythm Research Foundation
Arrhythmias, Cardiac
12/21
03/22
unCOVer-AF, NCT04830774: Natural History of COVID-19-Related Atrial Fibrillation

Recruiting
N/A
200
Europe, US
ILR, PMK, ICD
Texas Cardiac Arrhythmia Research Foundation
COVID-19, Atrial Fibrillation New Onset
12/21
12/23
REACT, NCT04726943: RF Applications for Residual LAA Leaks

Not yet recruiting
N/A
100
US
Radiofrequency Energy Applications
Texas Cardiac Arrhythmia Research Foundation
Left Atrial Appendage Thrombosis, Stroke, Ischemic, Atrial Fibrillation
02/22
12/22
NCT05229848: ICE Based Atrial Flutter Ablation Vs Conventional Fluoroscopy/Anatomical Mapping Based Ablation - ICE Flutter Study

Not yet recruiting
N/A
60
US
3D electroanatomical mapping alone guided CTI ablation, ICE plus 3D electroanatomical mapping guided CTI ablation
Kansas City Heart Rhythm Research Foundation
Atrial Flutter
04/22
04/22
MUSICAL, NCT04493970: HS Students Mandatory Universal Student Instruction in CPR Appraised Learning- Is the Mandate Working?

Recruiting
N/A
5000
US
High School Students Survey
Kansas City Heart Rhythm Research Foundation
Sudden Cardiac Arrest
10/24
10/24
MAVERIC, NCT05158751: Myocarditis Causing Premature Ventricular Contractions:Insights From the Registry

Not yet recruiting
N/A
100
US
Kansas City Heart Rhythm Research Foundation, Kansas City Heart Rhythm Institute
Myocarditis, Premature Ventricular Contractions, Ventricular Tachycardia (VT)
03/25
05/25
NCT05327101: Patient Preferences for Leadless Pacemakers

Completed
N/A
117
US
Patient Preference Survey
Abbott Medical Devices
Cardiac Rhythm Disorder, Bradycardia, Cardiac Pacemaker Artificial
06/23
06/23
aMAZE CAP, NCT04468334: aMAZE Trial Continued Access Protocol

Completed
N/A
82
US
LARIAT + PVI, LAA + RF PVI, LAA + Cryo PVI
AtriCure, Inc.
Atrial Fibrillation
04/23
04/23
NCT05450302: Assessing the Predictive Value of High Frequency Algorithm of PURE EP for Low Amplitude Signal Detection

Not yet recruiting
N/A
150
US
PURE EP (Observational Study)
Kansas City Heart Rhythm Research Foundation
Cardiac Arrhythmias
10/23
12/23
STEER-CLOSE, NCT05464511: Impact of Steerable Delivery Sheaths on Successful Closure of LA A With AMULET

Not yet recruiting
N/A
300
US
Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath.
Kansas City Heart Rhythm Research Foundation, Kansas City Heart Rhythm Institute
Atrial Fibrillation, Stroke
10/25
12/25
NCT06060548: Role of Novel ILR in the Management of PVCs

Recruiting
N/A
50
US
Monitoring of patients presenting with PVCs
Kansas City Heart Rhythm Research Foundation
PVC - Premature Ventricular Contraction, Myocarditis
12/24
03/25
COFFEE-AF, NCT05464940: Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction

Not yet recruiting
N/A
100
US
Intravenous caffeine, Masked Placebo
Kansas City Heart Rhythm Research Foundation, Kansas City Heart Rhythm Institute, Overland Park, KS, Texas Cardiac Arrhythmia Institute, Austin, TX, USA, Loma Linda University, Loma Linda, California, USA
Atrial Fibrillation
06/25
09/25
NCT06199414: Vascular Closure With Novel External Compression Device: The LockeT Study

Not yet recruiting
N/A
70
US
Venous Closure
Kansas City Heart Rhythm Research Foundation
Atrial Fibrillation, Hemostasis
10/24
12/24
Assert-IQ, NCT06172699: Implantable Cardiac Monitor (ICM) Post Market Study

Active, not recruiting
N/A
150
US
Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
Abbott Medical Devices
Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation
12/24
12/25
NCT06289413: Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study

Recruiting
N/A
400
US
Development of AD/OI after BS
Kansas City Heart Rhythm Research Foundation, Kansas City Heart and Rhythm Institute, Overland Park, KS, Bariatric and Metabolic Specialists, Overland Park, KS
Autonomic Dysfunction, Orthostatic Intolerance
12/24
12/24
MONITOR-AF, NCT06352060: Dynamic Data-Driven Management of Atrial Fibrillation Using Implantable Cardiac Monitors: The Study

Recruiting
N/A
2500
US
No intervention or administration will be performed due to the observational nature of the study
Kansas City Heart Rhythm Research Foundation
Atrial Fibrillation
11/24
12/24
NCT06223789: VOLT-AF IDE Clinical Study

Active, not recruiting
N/A
435
Europe, Canada, US, RoW
Pulsed Field Ablation
Abbott Medical Devices
Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
01/26
01/26
REDUCE-AF, NCT06465706: Assessing the Safety and Efficacy of the LAmbre™ Plus Device

Not yet recruiting
N/A
1826
NA
LAmbre investigational device
Kansas City Heart Rhythm Research Foundation
Atrial Fibrillation
10/29
01/30
ABT-CIP-10523, NCT06707688: Abbott Medical - VERITAS Study

Recruiting
N/A
475
Europe, Canada, US
Amulet™ 2 Left Atrial Appendage (LAA) Occluder
Abbott Medical Devices
Atrial Fibrillation (AF), Stoke
07/26
07/28
NCT06676072: A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects with PAF:

Recruiting
N/A
188
Europe, US
PFA Ablation catheter
Abbott Medical Devices
Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation
04/26
04/26
CATALYST, NCT04226547: Amplatzer Amulet LAAO vs. NOAC

Recruiting
N/A
2650
Europe, Canada, Japan, US, RoW
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC
Abbott Medical Devices
Atrial Fibrillation, Stroke, Bleeding
08/27
08/30
NCT06075628: Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closure: The CF-CT Registry

Recruiting
N/A
100
US
Left Atrial Appendage Occlusion
Kansas City Heart Rhythm Research Foundation
Atrial Fibrillation, Ischemic Stroke, Acute
12/24
12/24
NCT05464537: Efficacy Rate of Unipolar Polarity Switch for Lesion Assessment in Pulmonary Vein Isolation

Recruiting
N/A
30
US
Unipolar Polarity Switch Left, Unipolar Polarity Switch Right
Kansas City Heart Rhythm Research Foundation, Kansas City Heart Rhythm Institute, Overland Park, KS
Atrial Fibrillation
12/24
12/24
NCT06078735: Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study

Recruiting
N/A
110
US
Vascular closure with LockeT device
Kansas City Heart Rhythm Research Foundation
Atrial Fibrillation, Hemostasis
12/24
12/24
NCT06061757: Use of 4D-ICE in Conjunction With TEE for Left Atrial Appendage Closure

Recruiting
N/A
52
US
Imaging guidance with TEE and ICE for Left atrial appendage closure
Kansas City Heart Rhythm Research Foundation
Atrial Fibrillation, Stroke
12/24
12/25
RESTART, NCT05477147: Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

Active, not recruiting
N/A
92
Europe, US
Catheter Ablation
Volta Medical
Atrial Fibrillation
02/25
02/25
NCT06672861: Development and Validation of the Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)

Not yet recruiting
N/A
100
US
Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)
Kansas City Heart Rhythm Research Foundation, Kansas City Heart Rhythm Institute, Overland Park, KS, Midwest Heart and Vascular Specialists, Overland Park, KS
Cardiac Dysautonomia
12/25
12/25
NCT05826665: Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System

Recruiting
N/A
200
US
Persistent AF ablation assisted with the STAR Apollo Mapping System
Kansas City Heart Rhythm Research Foundation, Kansas City Heart Rhythm Institute, St. Bernards Medical Center, Sarasota Medical Center
Persistent Atrial Fibrillation
07/25
07/25
NCT06052358: Left Atrial Appendage Closure With WATCHMAN FLX Device in Recurrent Gastrointestinal Bleeding: The GI-FLX Registry

Recruiting
N/A
500
US
LAAC with Watchman FLX device
Kansas City Heart Rhythm Research Foundation, Kansas City Heart Rhythm Institute, Overland Park, Kansas, Texas Cardiac Arrythmia Institute, Austin, Texas, Los Robles Health System, Los Robles, California, Centennial Medical Center, Nashville, Tennessee
Atrial Fibrillation, GI Bleeding
08/25
08/25
NCT05280093: HEAL-IST IDE Trial

Recruiting
N/A
142
Europe, US
AtriCure ISOLATOR Synergy Surgical Ablation System
AtriCure, Inc.
Inappropriate Sinus Tachycardia
06/26
06/27
NCT05107635: Inappropriate Sinus Tachycardia Registry

Recruiting
N/A
500
Europe, US
AtriCure Commercially Available Devices
AtriCure, Inc.
Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome
01/27
01/27
NCT05997446: Amulet™ ADVANCE LAA

Active, not recruiting
N/A
610
US
Left atrial appendage occlusion (LAAO)
Abbott Medical Devices
Atrial Fibrillation, Stroke, Bleeding
06/27
06/27
COMPANION AI, NCT06056271: Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation

Recruiting
N/A
400
US
AF Ablation
Volta Medical, Heart Rhythm Clinical and Research Solutions, LLC
Atrial Fibrillation
12/27
12/27
DEFINE AFib, NCT04926857: (Atrial Fibrillation)

Completed
N/A
973
US
Non-Interventional
Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
01/24
01/24
NCT05839873: Abbott Ventricular Tachycardia PAS

Recruiting
N/A
150
US
FlexAbility SE Ablation Catheter
Abbott Medical Devices
Ventricular Tachycardia
08/28
11/28
NCT04431544: AcQMap® US Registry of Procedural and Long-term Clinical Outcomes (Discover-US)

Terminated
N/A
513
US
AcQMap System
Acutus Medical
Ablation of Arrhythmia's
11/23
11/23
NCT05139329: The ORCHESTRATE-Myocarditis Registry

Not yet recruiting
N/A
382
US
Imaging
Kansas City Heart Rhythm Research Foundation, Kansas City Heart Rhythm Institute, Texas Cardiac Arrhythmia Research Foundation, Montefiore Medical Center, Loma Linda University International Heart Institute
Myocarditis, Ischemia, Chest Pain
03/25
05/25
Kambhampati, Suman
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
NCT04530565: Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Recruiting
3
348
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, AMG-103, AMG103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI 538, MEDI-538, MEDI538, MT 103, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dasatinib, BMS 354825, BMS-354825, BMS354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Electrocardiography, ECG, EKG, Lumbar Puncture, LP, Spinal Tap, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, MUGA, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Ponatinib Hydrochloride, AP24534 HCl, Iclusig, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
07/28
07/28
S2209, NCT05561387: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Recruiting
3
510
US
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Daratumumab and Hyaluronidase-fihj, DARA Co-formulated with rHuPH20, DARA/rHuPH20, Daratumumab + rHuPH20, Daratumumab with rHuPH20, Daratumumab-rHuPH20, Daratumumab/Hyaluronidase-fihj, Daratumumab/rHuPH20 Co-formulation, Darzalex Faspro, Darzalex/rHuPH20, HuMax-CD38-rHuPH20, Recombinant Human Hyaluronidase Mixed with Daratumumab, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Plasma Cell Myeloma
03/30
04/30
SELECT-AML-1, NCT04905407 / 2021-003910-38: Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML

Active, not recruiting
2
95
Europe, US
Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza
Syros Pharmaceuticals, Syros Pharmaceuticals, Inc.
Acute Myeloid Leukemia
04/28
04/28
Benefit VA, NCT06520098: A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Not yet recruiting
2
100
US
Venetoclax, VENCLEXTA, Ibrutinib, Acalabrutinib, Zanubrutinib, IMBRUVICA, CALQUENCE, BRUKINSA
VA Office of Research and Development
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/30
12/30
KCP-8602-801, NCT02649790 / 2021-003810-38: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Checkmark From trial for myelodysplastic syndrome at ASH 2019
Dec 2019 - Dec 2019: From trial for myelodysplastic syndrome at ASH 2019
Active, not recruiting
1/2
277
Europe, Canada, US, RoW
KPT-8602, Eltanexor, ASTX727, Dexamethasone
Karyopharm Therapeutics Inc, Karyopharm Therapeutics Inc.
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
08/24
12/24
NHLBI-MDS, NCT02775383: The National Myelodysplastic Syndromes (MDS) Study

Active, not recruiting
N/A
3500
US, RoW
Therapeutic
National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Myelodysplastic Syndromes (MDS)
03/25
06/25
Mirza, Moben
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Investigator, Principal
OCEAN, NCT04986982 / 2020-001175-32: OpiCapone Effect on Motor Fluctuations and pAiN

Completed
4
144
Europe
Opicapone 50 mg, BIA 9-1067, Placebo
Bial - Portela C S.A., Bial - Portela & Ca, S.A.
Parkinson Disease
02/24
02/24
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy

Recruiting
4
100
US
Ketamine
University of Oklahoma
Hemorrhoids
01/25
07/25
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed
4
140
RoW
Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox
Daiichi Sankyo
COPD Exacerbation Acute
09/24
09/24
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct

Recruiting
4
150
RoW
Rifaximin 550 MG, Azithromycin 500 MG, Loperamide
Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences
Diarrhoea;Acute, Diarrhea Travelers
09/25
12/25
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

Not yet recruiting
4
100
US
Skin Cleanser Combination No.1
Boston Children's Hospital
Atopic Dermatitis
12/28
12/28
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

Not yet recruiting
4
40
US
fentanyl and Remimazolam
Indiana University, Indiana University Health
Dental Extraction
01/26
03/26
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Terminated
4
109
US
Tamsulosin Hydrochloride
University of Massachusetts, Worcester, UMass Memorial Health Care
Thoracic Diseases, Urinary Retention
10/23
10/23
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting
3
165
Europe, Canada, US, RoW
Macitentan, ACT-064992, Standard-of-care
Actelion
Pulmonary Arterial Hypertension
08/24
07/25
TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations

Hourglass Jul 2023 - Dec 2023 : Acceptance of regulatory submission for 2L+ NSCLC with or without actionable genomic alterations (based on TROPION-Lung01 trial)
Apr 2023 - Jun 2023: Topline results from TROPION-LUNG01 trial for metastatic NSCLC
Active, not recruiting
3
590
Europe, Canada, Japan, US, RoW
DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel
Daiichi Sankyo, AstraZeneca
Non-small Cell Lung Cancer
05/24
06/25
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Small Cell Lung Cancer
04/27
02/29
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Not yet recruiting
3
632
RoW
docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy
Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
06/24
06/26
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

Recruiting
3
50
US
Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol
Planned Parenthood League of Massachusetts
Abortion
07/24
09/24
HERTHENA-Lung02, NCT05338970 / 2021-005879-40: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, not recruiting
3
586
Europe, Canada, Japan, US, RoW
Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy
Daiichi Sankyo, Merck Sharp & Dohme LLC
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
05/24
06/26
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Not yet recruiting
3
1500
US
Transdermal system containing progestin
Mylan Pharmaceuticals Inc
Female Contraception
03/27
04/27
VDJ001-RA-Ⅲ, NCT06726096: Phase III Trial of VDJ001 in Patients with Moderate-to-severe Active Rheumatoid Arthritis

Not yet recruiting
3
615
RoW
Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Beijing VDJBio Co., LTD.
Rheumatoid Arthritis (RA)
12/25
12/26
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Not yet recruiting
3
78
Europe
Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Swedish Orphan Biovitrum, PSI CRO
Severe Haemophilia A
08/26
08/26
frontMIND, NCT04824092 / 2020-002990-84: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Calendar Jul 2025 - Dec 2025: Primary analysis data from frontMIND trial in combination with Revlimid for newly diagnosed DLBCL
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at EHA 2021
Hourglass Jun 2021 - Jun 2021 : Updated data from frontMIND trial for newly diagnosed DLBCL at ASCO 2021
Active, not recruiting
3
899
Europe, Canada, Japan, US, RoW
Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo
Incyte Corporation
Diffuse Large B-cell Lymphoma
06/25
05/26
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Active, not recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
 

Download Options